Skip to content

US · PEPG · BIOTECHNOLOGY

PepGen Inc. (PEPG) intrinsic value and stock valuation

$3.78as of 2026-11-21 · Mkt cap 136.96M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

PepGen Inc. DCF and intrinsic value

InvestorsCraft values PEPG with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PEPG’s statements →

PepGen Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02118 pepgen.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-89.66M
20192025
Free cash flow
-$-81.9M
20192025
Total equity
$147.4M+72.1% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-93.61M-$-97.74M-$-84.77M-$-68.3M-$-27.11M
Net income-$-89.66M-$-89.98M-$-78.63M-$-69.1M-$-27.28M
EPSd-$-2.12M-$-2.85M-$-3.3M-$-4.42M-$-1.22M
Operating cash flow-$-81.64M-$-82.37M-$-69M-$-59.27M-$-22.6M
Capital expenditure-$-260K-$-500K-$-2.6M-$-3.75M-$-500K
Free cash flow-$-81.9M-$-82.87M-$-71.6M-$-63.02M-$-23.1M
Total assets$173.9M$150.9M$143.1M$217.4M$143.6M
Total debt$17M$18.7M$20.1M$24.5M$0.00
Net debt-$-43.51M-$-30.76M-$-60.67M-$-157.22M-$-132.9M
Total equity$147.4M$118.6M$108.4M$179.6M$133.1M
Cash and short-term investments$148.5M$120.2M$110.4M$181.8M$132.9M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$1.4M$1.5M$1.18M$0.00$0.00
Gross profit-$-1.4M-$-1.5M-$-1.18M$0.00$0.00
Research and development expenses$71M$76.5M$68.1M$54.1M$23.8M
Selling, general and administrative expenses$22.6M$21.3M$16.6M$14.2M$8.11M
Other expenses-$-1.4M-$-1.5M-$-1.18M$0.00-$-4.8M
Operating expenses$92.2M$96.2M$83.6M$68.3M$27.1M
Cost and expenses$93.6M$97.7M$84.8M$68.3M$27.1M
Interest income$4.02M$7.14M$6.4M$2.79M$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.4M$1.5M$1.18M$490K$180K
Ebitda-$-88.21M-$-89.09M-$-77.37M-$-64.91M-$-27.1M
Operating income-$-93.61M-$-97.74M-$-84.77M-$-68.3M-$-27.11M
Total other income/expenses, net$4.01M$7.14M$6.21M$2.9M-$-170K
Income before tax-$-89.61M-$-90.6M-$-78.55M-$-65.4M-$-27.28M
Income tax expense$50K-$-620K$70K$3.71M$0.00
Net income-$-89.66M-$-89.98M-$-78.63M-$-69.1M-$-27.28M
Weighted average shares outstanding$42.2M$31.6M$23.8M$15.6M$22.4M
Weighted average diluted shares outstanding$42.2M$31.6M$23.8M$15.6M$22.4M
Balance sheet
20252024202320222021
Cash and short-term investments$148.5M$120.2M$110.4M$181.8M$132.9M
Net receivables$0.00$0.00$0.00$60K$4.74M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$151M$123.8M$112.7M$186.1M$140M
Property, plant and equipment, net$21M$25.2M$28.4M$29.9M$640K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$1.47M
Total non-current assets$22.9M$27.1M$30.4M$31.4M$3.65M
Total assets$173.9M$150.9M$143.1M$217.4M$143.6M
Accounts payable$820K$1.75M$1M$1.36M$3.24M
Short-term debt$3.19M$3.09M$3M$5.55M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$12.7M$16.7M$17.5M$18.8M$10.3M
Long-term debt$13.8M$15.6M$17.1M$19M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$13.8M$15.6M$17.1M$19M$230K
Capital lease obligations$3.19M$18.7M$20.1M$24.5M$0.00
Total liabilities$26.5M$32.3M$34.6M$37.8M$10.6M
Common stock$10K$0.00$0.00$0.00$0.00
Retained earnings-$-361.12M-$-271.46M-$-181.48M-$-102.86M-$-33.75M
Accumulated other comprehensive income (loss)$10K$20K$30K-$-80K$20K
Total equity$147.4M$118.6M$108.4M$179.6M$133.1M
Total investments$87.9M$70.8M$29.6M$0.00$1.47M
Total debt$17M$18.7M$20.1M$24.5M$0.00
Net debt-$-43.51M-$-30.76M-$-60.67M-$-157.22M-$-132.9M
Cash flow statement
20252024202320222021
Net income-$-89.66M-$-89.98M-$-78.63M-$-69.1M-$-27.28M
Depreciation and amortization$5.14M$5.25M$850K$490K$180K
Stock-based compensation$10.6M$11.5M$7.05M$4.76M$1.53M
Change in working capital-$-6.22M-$-5.25M$1.95M$4.51M$2.77M
Accounts receivable$0.00$0.00$30K$4.18M-$-4.34M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-940K$720K-$-370K-$-1.41M$2.51M
Net cash provided by operating activities-$-81.64M-$-82.37M-$-69M-$-59.27M-$-22.6M
Investments in property, plant and equipment-$-260K-$-500K-$-2.6M-$-3.75M-$-500K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-15.23M-$-37.67M-$-32M-$-3.75M-$-500K
Common stock issued$108.1M$86.8M$0.00$114.3M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$108M$88.8M-$-190K$112.2M$147.7M
Net change in cash$11.1M-$-31.35M-$-100.9M$48.9M$124.6M
Cash at end of period$62.1M$51M$82.3M$183.2M$134.4M
Operating cash flow-$-81.64M-$-82.37M-$-69M-$-59.27M-$-22.6M
Capital expenditure-$-260K-$-500K-$-2.6M-$-3.75M-$-500K
Free cash flow-$-81.9M-$-82.87M-$-71.6M-$-63.02M-$-23.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About PepGen Inc.

        PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

        CEO
        James McArthur
        Employees
        56
        Beta
        1.88

        Explore

        Frequently asked questions

        What is the intrinsic value of PepGen Inc. (PEPG)?

        InvestorsCraft does not currently publish an intrinsic value for PEPG. How the IC value is calculated.

        Is PEPG undervalued?

        InvestorsCraft does not publish an undervaluation signal for PEPG at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.